No Data
No Data
Harbin Pharmaceutical Group (600664.SH) plans to establish a joint venture with Qitaihe City Investment to carry out fermentation project construction.
On July 30th, Gelunhui reported that Harbin Pharmaceutical Group (600664.SH) plans to establish a joint venture with Qitaihe City Investment in Qitaihe City, in order to further improve the layout of the company's industry chain, enhance the integration advantage of raw materials and preparations, increase the company's product competitiveness, and conduct fermentation project construction. The registered capital of the joint venture is 0.145 billion yuan, the company contributes approximately 74.24 million yuan in equipment as capital, holding 51% of the joint venture's equity, and Qitaihe City Investment contributes 71.32 million yuan in cash, holding 49% of the joint venture's equity. This external investment is in line with the company's global strategy.
Harbin Pharmaceutical Group (600664.SH): currently has five main research and development entities.
Harbin Pharmaceutical Group (600664.SH) disclosed its investor relations activity record, which showed that the company currently has five main research and development subjects. It has established the Ha Yao Da Jiankang Research Institute, the Ha Yao Group Technology Center, and Ha Yao (Beijing) Biotechnology Co., Ltd. which focus on the research and development of OTC drugs, health products, generic drugs and innovative drugs, respectively. At the same time, the research and development teams for traditional Chinese medicine products and biological products are respectively focused on the upgrading of traditional Chinese medicine products and the development of biological products, forming a diversified research and development system.
Harbin Pharmaceutical Group (600664.SH): Plans to achieve revenue of 16.461 billion yuan in 2024, a year-on-year growth of 6.5%.
According to the investment relations activity record disclosed by Harbin Pharmaceutical Group (600664.SH) on July 18th, the company plans to achieve a revenue of 16.461 billion yuan in 2024, a year-on-year growth of 6.5%; the net income attributable to shareholders of the listed company excluding non-recurring gains and losses is 0.353 billion yuan, a year-on-year growth of 8.5%. At the same time, the company will control product production costs and various expenses and actively seek and cultivate new profit growth points. The above business goals do not represent the company's profit forecast for 2024, do not constitute the company's performance commitments to investors, and the company's actual operating conditions are subject to various internal and external factors.
Is Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Latest Stock Performance A Reflection Of Its Financial Health?
Announcement of Half-Year Performance Forecast Increase for HAECO Group Co., Ltd. in 2024.
Harbin Pharmaceutical Group (600664.SH) has issued a profit forecast, with an expected net income of 0.312 to 0.375 billion yuan, a year-on-year increase of 71% to 105%.
Harbin Pharmaceutical Group (600664.SH) has released a performance forecast for the first half of 2024, with the company expecting...
No Data